Observational analysis demonstrates distinct CD14 and CD16 monocyte patterns across disease stages, indicating CD14+CD16-low subsets predict non-progressive HIV.
Monocytes are phenotypically pliable, which allows them to play several significant immunological roles in combating HIV infection. Monocytes can be subcategorized into subsets based on the expression of CD14 and CD16 antigens. Although the CD4+ T cell counts have been shown to predict HIV viremia, the actual predictive value of these monocyte subsets at different stages of plasma viremia is not known. We derived ex-vivo monocytes from HIV+ patients with detectable and below detectable plasma viremia, HIV+ Long-Term Non-Progressors (LTNP) and HIV negative individuals. We subdivided monocytes into CD14+/ CD16-low, medium and high populations and visualized the phenotypic changes in expression of both CD14 and CD16 antigens in HIV+ patients at different stages of HIV disease.
No takes yet. Share an insight, caveat, or question.
A 2018 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: